Jamie R. Brewer

Hematology | Oncology

5841 S Maryland Ave
Chicago, IL 60637

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy.

FDA Approval Summary: Lifileucel for Unresectable or Metastatic Melanoma Previously Treated with an Anti-PD-1-Based Immunotherapy.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 11, 2025

A call to action to advance patient-focused and decentralized clinical trials.

A call to action to advance patient-focused and decentralized clinical trials.

Journal: Cancer

Published: January 09, 2024

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer.

Journal: Bladder cancer (Amsterdam, Netherlands)

Published: July 27, 2023

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.

FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 19, 2023

Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data.

Addressing Barriers to Clinical Trial Participation for Transgender People With Cancer to Improve Access and Generate Data.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 27, 2022

A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.

A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.

Journal: European urology

Published: October 27, 2022

Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.

Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials.

Journal: The Lancet. Oncology

Published: March 29, 2021

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies.

Regulatory Considerations for Contribution of Effect of Drugs Used in Combination Regimens: Renal Cell Cancer Case Studies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 02, 2020

An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.

An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 03, 2019

Chemotherapy-induced peripheral neuropathy: Current status and progress.

Chemotherapy-induced peripheral neuropathy: Current status and progress.

Journal: Gynecologic oncology

Published: September 05, 2015

Showing 1-10 of 10

Last Updated: 09/26/2026